AQS1303 is designed to be a once-daily, and up to a once-weekly transdermal form of doxylamine/pyridoxine.

Doxylamine/pyridoxine is currently marketed as Diclegis (US)/Diclecitin® (Canada) for the treatment of nausea and vomiting of pregnancy, as an oral tablet dosed up to four times per day. Diclegis is the only FDA approved medication for morning sickness in pregnant women. A long-acting transdermal form of doxylamine/pyridoxine is being developed by Aequus to address the risk of missed doses due to emesis (vomiting).

Aequus has engaged with over 50 physicians and over 200 patients to understand the unmet need in this indication. The results from these discussions were:

    • 34-37% of women take prescription medication to manage their nausea and vomiting during pregnancy
    • Taking oral medication is a challenge for patients suffering from nausea and vomiting

Market Need


Nausea and Vomiting of Pregnancy (NVP) affects ~53% of women. The indication is most commonly known as, “morning sickness,” however 80% of women have prospectively reported their symptoms of NVP to last throughout the entire day. NVP is most common in the first trimester, yet in some severe cases women may experience NVP throughout their entire pregnancy. -  (read more...)